2-amino-5-(benzyloxy)benzamide | 65883-84-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-5-(benzyloxy)benzamide
• 英文别名: 5-Benzyloxyanthranilamide；2-amino-5-phenylmethoxybenzamide
• CAS: 65883-84-3
• 化学式: C₁₄H₁₄N₂O₂
• 分子量: 242.277
• InChiKey: GOAPPDCNKZJTMK-UHFFFAOYSA-N

物化性质

• 沸点：
  409.6±35.0 °C(Predicted)
• 密度：
  1.241±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  78.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-amino-5-(benzyloxy)benzamide 在 盐酸 、 三氯氧磷 作用下， 生成 4-氯-6-(苯基甲氧基)-喹唑啉
  参考文献：
  名称：

  Structure–activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-α production and T Cell proliferation

  摘要：

  We synthesized 4-chlorophenethylaminoquinazoline derivatives and evaluated their inhibitory activities toward both TNF-alpha production and T cell proliferation responses; Compound 2f, containing a piperazine ring at the C(7)-position of the quinazoline ring, exhibited more potent inhibitory activities toward both than the lead compound 1a. A smaller N-substituent in the piperazine ring was required for inhibition of TNF-alpha production. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00718-6
• 作为产物：
  描述：

  2-Nitro-5-phenylmethoxybenzoyl chloride 在 ammonium hydroxide 、 水 、 铁粉 、 氯化铵 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 2.5h， 生成 2-amino-5-(benzyloxy)benzamide
  参考文献：
  名称：

  SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

  摘要：

  本发明提供了一种新型酰胺衍生物，具有基质金属蛋白酶抑制活性，并且作为药用剂是有用的，该化合物由以下式(I)表示，其中环A是一个可选择取代的含氮杂环，环B是一个可选择取代的单环同核环或可选择取代的单环杂环，Z是N或NR1（R1是氢原子或可选择取代的碳氢基团），是一个单键或双键，R2是氢原子或可选择取代的碳氢基团，X是一个具有1到6个原子的可选择取代的间隔物，环C是（1）一个可选择取代的同核环或（2）一个除了由（II）表示的环之外的可选择取代的杂环（X′是S、O、SO或CH2），并且环B和环C中至少有一个有取代基，但不包括N-{(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺，或其盐。

  公开号：

  US20150329556A1

文献信息

• [EN] HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR<br/>[FR] COMPOSÉ AMIDE HETEROCYCLIQUE ET UTILISATION DE CELUI-CI EN TANT QU'INHIBITEUR MMP-13
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005105760A1

  公开（公告）日：2005-11-10

  The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), - - - is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionnally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X’ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

  本发明提供了一种新型酰胺衍生物，具有基质金属蛋白酶抑制活性，并且作为药用剂是有用的，该化合物由以下式(I)表示，其中环A是一个可选择取代的含氮杂环，环B是一个可选择取代的单环同核环或可选择取代的单环杂环，Z是N或NR1（R1是氢原子或可选择取代的碳氢基团），- - - 是一个单键或双键，R2是氢原子或可选择取代的碳氢基团，X是具有1到6个原子的可选择取代的间隔物，环C是(1)一个可选择取代的同核环或(2)除了由(II)表示的环之外的可选择取代的杂环（X'是S、O、SO或CH2），并且环B和环C中至少有一个具有取代基，但不包括N-(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]-2-羟基丙基}-5,6-二甲基-4-氧代-1,4-二氢噻吩[2,3-d]嘧啶-2-羧酰胺或其盐。
• 1-Heterocyclic alkyl-1,2,3,4-tetrahydroquinazolinones and analgesic
  申请人：Pennwalt Corporation

  公开号：US04205173A1

  公开（公告）日：1980-05-27

  1-Heterocyclic alkyl-1,2,3,4-tetrahydroquinazolinones, acid addition salts thereof, and intermediate compounds having analgesic properties. A representative quinazolinone compound is 1-[2-(1-phenyl-4-piperazinyl)-ethyl]-2-phenyl-1,2,3,4-tetrahydro-4-quinazo linone. A representative analgesic intermediate is 2-[2-(4-[1-phenyl]piperazinyl)ethylamino] bezamide.

  杂环烷基-1,2,3,4-四氢喹唑啉酮，其酸盐以及具有镇痛性质的中间化合物。代表性的喹唑啉酮化合物是1-[2-(1-苯基-4-哌嗪基)-乙基]-2-苯基-1,2,3,4-四氢-4-喹唑啉酮。代表性的镇痛中间体是2-[2-(4-[1-苯基]哌嗪基)乙基氨基]苯甲酰胺。
• Structure–activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-α production and T Cell proliferation
  作者：Masanori Tobe、Yoshiaki Isobe、Hideyuki Tomizawa、Mitsuhiro Matsumoto、Fumihiro Obara、Takahiro Nagasaki、Hideya Hayashi

  DOI：10.1016/s0960-894x(00)00718-6

  日期：2001.2

  We synthesized 4-chlorophenethylaminoquinazoline derivatives and evaluated their inhibitory activities toward both TNF-alpha production and T cell proliferation responses; Compound 2f, containing a piperazine ring at the C(7)-position of the quinazoline ring, exhibited more potent inhibitory activities toward both than the lead compound 1a. A smaller N-substituent in the piperazine ring was required for inhibition of TNF-alpha production. (C) 2001 Elsevier Science Ltd. All rights reserved.
• Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists
  作者：István Borza、Sándor Kolok、Kornél Galgóczy、Anikó Gere、Csilla Horváth、Sándor Farkas、István Greiner、György Domány

  DOI：10.1016/j.bmcl.2006.10.033

  日期：2007.1

  A novel series of kynurenic acid amides, ring-enlarged derivatives of indole-2-carboxamides, was prepared and identified as in vivo active NR2B subtype selective NMDA receptor antagonists. The synthesis and SAR studies are discussed. (c) 2006 Elsevier Ltd. All rights reserved.
• HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1740551B1

  公开（公告）日：2012-09-12